{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:30:46Z","timestamp":1768217446531,"version":"3.49.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is one of the primary targets of statin drugs, in prostate cancer (PCa) remains controversial. This study aimed to investigate the causal relationship of genetically instrumented HMGCR inhibition with the therapeutic role of PCa through Mendelian randomization (MR) and validate the findings by cell experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We selected single nucleotide polymorphisms (SNPs) associated with statins use by targeting HMGCR. We used three genome-wide association studies (GWASs) datasets for PCa: PCa (GWAS ID:ieu-b-85, Sample size = 140,254), PCa (GWAS ID:ieu-b-4809, Sample size = 182,625), PCa (GWAS ID:ebi-a-GCST006085, Sample size = 140,254). The inverse variance weighted (IVW) method served as the primary MR approach to validate the suitability of the selected SNPs and to explore the causal relationship between statins use and PCa. To assess the robustness of the MR findings, a comprehensive sensitivity analysis, steiger directionality tests and colocalization analyses were performed. Finally, we validated the MR findings by treating two PCa cell lines with Atorvastatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We ultimately selected 7 SNPs associated with HMGCR. The IVW results indicated that HMGCR inhibition decreased the risk of PCa. Per 1 standard deviation (SD, mg\/dL) decrease in low-density lipoprotein cholesterol (LDL-C) was associated with a 16.7% reduction in PCa risk: PCa (GWAS ID: ieu-b-85, Sample size = 140,254) (odds ratio (OR) = 0.833; 95% confidence interval (CI) = 0.726\u20130.954; P-adjusted = 0.014); Per 1 SD (mg\/dL) decrease in LDL-C was associated with a 1.5% reduction in PCa risk: PCa (GWAS ID: ieu-b-4809, Sample size = 182,625) (OR = 0.985; 95% CI = 0.973\u20130.998; P-adjusted = 0.023) and 16.2% reduction in PCa risk: PCa (GWAS ID: ebi-a-GCST006085, Sample size = 140,254) (OR = 0.838; 95% CI = 0.734\u20130.956; P-adjusted = 0.014). Results of sensitivity analysis showed MR finding was robust. However, our colocalization results indicated that no shared genetic variants were found in the HMGCR region. Results of cell experiments also demonstrated that statins use could promote apoptosis of PCa cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HMGCR inhibition reduces the risk of PCa, and this protective effect is independent of its lipid-lowering action. Our findings provide strong genetic support for initiating RCTs to investigate the therapeutic potential of statins for partial PCa patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1701869","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:17:59Z","timestamp":1768205879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of genetically instrumented HMGCR inhibition with the therapeutic role of prostate cancer: a Mendelian randomization study and supporting in vitro experiments"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaojie","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjun","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrurol.2016.199","article-title":"The current evidence on statin use and prostate cancer prevention: are we there yet?","volume":"14","author":"Alfaqih","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41391-025-00964-x","article-title":"The association between statin use, genetic variation, and prostate cancer risk","volume":"28","author":"Amiri","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.urolonc.2024.08.023","article-title":"Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial","volume":"43","author":"Chavarriaga","year":"2025","journal-title":"Urol. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3350\/cmh.2025.0541","article-title":"Prospects of Mendelian randomization in hepatology: a comprehensive literature review with practice guidance","volume":"31","author":"Chen","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41391-022-00554-1","article-title":"Statins and prostate cancer-hype or hope? The epidemiological perspective","volume":"25","author":"Craig","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1370\/afm.3011","article-title":"Patient communication preferences for prostate cancer screening discussions: a scoping review","volume":"21","author":"Fong","year":"2023","journal-title":"Ann. Fam. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41564-023-01363-5","article-title":"Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer","volume":"8","author":"Han","year":"2023","journal-title":"Nat. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e73873","DOI":"10.7554\/eLife.73873","article-title":"Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study","volume":"10","author":"Huang","year":"2021","journal-title":"Elife"},{"key":"B10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejca.2022.04.005","article-title":"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER","volume":"170","author":"Joshua","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41391-020-0207-5","article-title":"Associations among statins, preventive care, and prostate cancer mortality","volume":"23","author":"Kumar","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","article-title":"Comparative cardiovascular benefits of bempedoic acid and Statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.molmet.2019.04.003","article-title":"An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer","volume":"25","author":"Longo","year":"2019","journal-title":"Mol. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"103494","DOI":"10.1016\/j.ebiom.2021.103494","article-title":"Statins and adrenal androgen levels in prostate cancer: a new twist","volume":"70","author":"Mostaghel","year":"2021","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.euf.2016.05.004","article-title":"Statin use and prostate cancer survival in the Finnish randomized study of screening for prostate cancer","volume":"3","author":"Murtola","year":"2017","journal-title":"Eur. Urol. Focus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11883-024-01265-9","article-title":"Statin therapy in primary and secondary cardiovascular disease prevention","volume":"27","author":"Paparodis","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbi.2021.07.009","article-title":"Associations of immunological proteins\/traits with schizophrenia, major depression and bipolar disorder: a bi-directional two-sample Mendelian randomization study","volume":"97","author":"Perry","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2022.05.008","article-title":"A healthy lifestyle in men at increased genetic risk for prostate cancer","volume":"83","author":"Plym","year":"2023","journal-title":"Eur. Urol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"114197","DOI":"10.1016\/j.ejca.2024.114197","article-title":"Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: exploratory analysis of the SPARTAN trial","volume":"211","author":"Roy","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2527988","DOI":"10.1001\/jamanetworkopen.2025.27988","article-title":"Statin use in patients with advanced prostate cancer in the TITAN and SPARTAN trials","volume":"8","author":"Roy","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur. Urol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2022.12.021","article-title":"Genetic risk prediction for prostate cancer: implications for early detection and prevention","volume":"83","author":"Seibert","year":"2023","journal-title":"Eur. Urol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s12885-025-13895-6","article-title":"The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo","volume":"25","author":"Sekine","year":"2025","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/aje\/kwi203","article-title":"Statins and prostate cancer risk: a case-control study","volume":"162","author":"Shannon","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4103\/1008-682x.190327","article-title":"Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review","volume":"19","author":"Tan","year":"2017","journal-title":"Asian J. Androl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00345-021-03858-4","article-title":"The role of metformin, statins and diet in men on active surveillance for prostate cancer","volume":"40","author":"Tiwari","year":"2022","journal-title":"World J. Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2456825","DOI":"10.1001\/jamanetworkopen.2024.56825","article-title":"Trends in prostate cancer incidence and mortality rates","volume":"8","author":"Van Blarigan","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2018.11.033","article-title":"Prostate cancer incidence and mortality among men using statins and Non-statin lipid-lowering medications","volume":"112","author":"Van Rompay","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-025-13750-8","article-title":"Vasectomy and prostate cancer risk: a pooled of cohort studies and Mendelian randomization analysis","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.5167\/uzh-58181","article-title":"Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin","volume":"7","author":"Wong","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jcpt.13092","article-title":"The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone\/enzalutamide: a systematic review and meta-analysis","volume":"45","author":"Yang","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jare.2024.12.020","article-title":"Advances in statin adverse reactions and the potential mechanisms: a systematic review","volume":"76","author":"Zeng","year":"2025","journal-title":"J. Adv. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"119509","DOI":"10.1016\/j.jad.2025.119509","article-title":"Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: a drug target and mediation Mendelian randomization","volume":"388","author":"Zhang","year":"2025","journal-title":"J. Affect Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"100434","DOI":"10.1016\/j.advnut.2025.100434","article-title":"Homocysteine and multiple health outcomes: an outcome-wide umbrella review of meta-analyses and mendelian randomization studies","volume":"16","author":"Zhou","year":"2025","journal-title":"Adv. Nutr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12894-022-01120-6","article-title":"Association of triglyceride levels and prostate cancer: a Mendelian randomization study","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Urol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1701869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:18:01Z","timestamp":1768205881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1701869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":37,"alternative-id":["10.3389\/fphar.2025.1701869"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1701869","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1701869"}}